文献速递腹部USMR

对比增强超声与肝脏特异性对比剂MRI诊断肝细胞腺瘤与局灶性结节性增生的效能比较

Performance of Contrast-Enhanced Sonography Versus MRI With a Liver-Specific Contrast Agent for Diagnosis of Hepatocellular Adenoma and Focal Nodular Hyperplasia.
PubMed 文献 · AJR Am J Roentgenol · 2019-10-01

该前瞻性研究纳入因怀疑肝细胞腺瘤(HCA)或局灶性结节性增生(FNH)转诊至三级中心的连续患者,比较六氟化硫对比增强超声(CEUS)与钆贝葡胺肝脏特异性对比剂MRI的诊断效能。CEUS与MRI结果一致者占73%,不一致且经组织病理学证实者中MRI诊断正确率87.5%、CEUS为12.5%(p<0.05)。MRI的敏感度、特异度均为95%,CEUS分别为85%和87%。

要点

  • CEUS与肝脏特异性对比剂MRI诊断HCA和FNH的一致性为中等(一致率73%)。
  • 两者结果不一致且经病理证实时,MRI诊断正确率87.5%高于CEUS的12.5%(p<0.05)。
  • MRI诊断HCA和FNH的敏感度、特异度均为95%,CEUS分别为85%和87%。

核心结论

  • CEUS与肝脏特异性对比剂MRI诊断HCA和FNH的一致性为中等,在结果不一致且经组织病理学证实的病例中,肝脏特异性对比剂MRI诊断正确率显著高于CEUS。

研究设计与样本

  • 前瞻性研究,纳入因怀疑HCA或FNH转诊至三级中心的连续患者,初次分析共181例。
  • 所有患者均行六氟化硫CEUS和钆贝葡胺肝脏特异性对比剂MRI检查。
  • CEUS与MRI结果一致即判定诊断明确,不一致者行组织病理学检查(HPE)作为参考标准。
  • 进一步分析纳入结果一致或经HPE证实的156例患者,主要分析基于患者水平。

诊断标准与关键数值

  • CEUS诊断HCA和FNH的敏感度85%、特异度87%,ROC AUC为0.856,阳性预测值79%、阴性预测值90%。
  • 肝脏特异性对比剂MRI诊断HCA和FNH的敏感度95%、特异度95%,ROC AUC为0.949,阳性预测值92%、阴性预测值97%。
  • CEUS与MRI结果一致132例(73%)、不一致49例(27%)。
  • 49例结果不一致者中26例(53%)行HPE,其中2例结果不确定;剩余24例中MRI正确21例(87.5%)、CEUS正确3例(12.5%)(p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this article is to compare contrast-enhanced sonography (CEUS) with sulfur hexafluoride with MRI with the liver-specific contrast agent gadobenate dimeglumine in the diagnosis of hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH) in a cohort of consecutive patients. MATERIALS AND METHODS. Patients referred to a tertiary center for hepatobiliary disease who had suspected HCA or FNH on MRI performed with an extracellular gadolinium-based contrast agent underwent a prospective workup including CEUS and MRI with a liver-specific contrast agent. Diagnosis was definite when the findings of CEUS and MRI with a liver-specific contrast agent were concordant; histopathologic examination (HPE) was performed for cases with discordant findings. Descriptive statistics and the association between categoric variables were presented as numbers and percentages and were assessed using the Fisher exact test. The primary analysis was patient based. Sensitivity, specificity, and AUC and predictive values for the diagnosis of HCA and FNH were calculated separately for CEUS and MRI with a liver-specific contrast agent. RESULTS. A total of 181 patients were selected for the first analysis. Findings from CEUS and MRI with a liver-specific contrast agent were concordant for 132 patients (73%) and discordant for 49 (27%). HPE was performed for 26 of the 49 patients with discordant findings (53%), with findings indeterminate for two of these patients, the findings of MRI with a liver-specific contrast agent correct for 21 of the remaining 24 patients (87.5%), and the findings of CEUS correct for three of these 24 patients (12.5%) (p < 0.05). For further analysis, 156 patients with concordant findings or HPE-proven cases were included. For CEUS, the sensitivity and specificity for the diagnosis of HCA and FNH were 85% and 87%, respectively; the ROC AUC value was 0.856; and the positive predictive value and negative predictive value were 79% and 90%, respectively. For MRI with a liver-specific contrast agent, the sensitivity and specificity were 95% each, the ROC AUC value was 0.949, and the positive predictive value and negative predictive value were 92% and 97%, respectively, for the diagnosis of HCA and FNH. CONCLUSION. The findings of CEUS and MRI with a liver-specific contrast agent showed fair agreement for the diagnosis of HCA and FNH. MRI with a liver-specific contrast agent is diagnostically correct significantly more often than CEUS in cases with discordant findings that are HPE proven.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Bröker MEE, Taimr P, de Vries M, et al. Performance of Contrast-Enhanced Sonography Versus MRI With a Liver-Specific Contrast Agent for Diagnosis of Hepatocellular Adenoma and Focal Nodular Hyperplasia. AJR Am J Roentgenol. 2019. PMID: 31573852. doi:10.2214/AJR.19.21251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。